Evidence map›Paper›PMID 25526228›Full record

Trial reportPostgraduate medicine2015

rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts.

Kenneth Blum, Yijun Liu, Wei Wang, Yarong Wang, Yi Zhang, Marlene Oscar-Berman, Andrew Smolen, Marcelo Febo, David Han, Thomas Simpatico and 3 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Postgraduate medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Opioid-Induced Nodding-Not a Nice Nap.Acta scientific neurology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Are We Getting High Cause the Thrill is Gone?Journal of addiction psychiatry · 2023
    Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 4 countries.

Kenneth BlumDepartment of Psychiatry & McKnight Brain Institute, University of Florida, College of Medicine , Gainesville, FL , USA.
Yijun Liu
Wei Wang
Yarong Wang
Yi Zhang
Marlene Oscar-Berman
Andrew Smolen
Marcelo Febo
David Han
Thomas Simpatico
Frans J Cronjé
Zsolt Demetrovics
Mark S Gold
University of Florida · USXidian University · CNAir Force Medical University · CNBoston University · USEötvös Loránd University · HUStellenbosch University · ZATang Du Hospital · CNThe University of Texas at San Antonio · USUniversity of Colorado Boulder · USUniversity of Vermont · US

Funding

AFFECTIVE AND CONATIVE CHANGES IN ALCOHOLISMR01AA007112 · NIAAA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BERMAN, MARLENE OSCAR · 1987 to 2019
$8.3M
AFFECTIVE AND CONATIVE CHANGES IN ALCOHOLISMK05AA000219 · NIAAA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BERMAN, MARLENE OSCAR · 1997 to 2011
$1.8M
Alcoholism and Brain FunctionsI01CX000326 · VA · VA BOSTON HEALTH CARE SYSTEM · PI BERMAN, MARLENE OSCAR · 2011 to 2014
–
CSRD VA I01 CX000326NIAAA NIH HHS K05 AA000219NIAAA NIH HHS R01 AA007112
6 · The paper itself

Abstract

Recently, Willuhn et al. reported that cocaine use and even non-substance-related addictive behavior increases as dopaminergic function is reduced. Chronic cocaine exposure has been associated with decreases in D2/D3 receptors and was also associated with lower activation of cues in occipital cortex and cerebellum, in a recent PET study by Volkow's et al. Therefore, treatment strategies, like dopamine agonist therapy, that might conserve dopamine function may be an interesting approach to relapse prevention in psychoactive drug and behavioral addictions. To this aim, we evaluated the effect of KB220Z™ on reward circuitry of 10 heroin addicts undergoing protracted abstinence (average 16.9 months). In a randomized placebo-controlled crossover study of KB220Z, five subjects completed a triple-blinded experiment in which the subject, the person administering the treatment, and the person evaluating the response to treatment were blinded to the treatment that any particular subject was receiving. In addition, nine subjects were genotyped utilizing the GARSDX™ test. We preliminarily report that KB220Z induced an increase in BOLD activation in caudate-accumbens-dopaminergic pathways compared to placebo following 1-hour acute administration. Furthermore, KB220Z also reduced resting-state activity in the putamen of abstinent heroin addicts. In the second phase of this pilot study of all 10 abstinent heroin-dependent subjects, we observed that three brain regions of interest were significantly activated from resting state by KB220Z compared to placebo (p < 0.05). Increased functional connectivity was observed in a putative network that included the dorsal anterior cingulate, medial frontal gyrus, nucleus accumbens, posterior cingulate, occipital cortical areas, and cerebellum. These results and other quantitative electroencephalogy (qEEG) study results suggest a putative anti-craving/anti-relapse role of KB220Z in addiction by direct or indirect dopaminergic interaction. Due to small sample size, we caution definitive interpretation of these preliminary results, and confirmation with additional research and ongoing rodent and human studies of KB220Z is required.

Indexed as

AdultAlgorithmsBrainBrain ChemistryCatecholaminesCross-Over StudiesDopamine AgonistsElectroencephalographyFemaleFunctional NeuroimagingGenotyping TechniquesHeroin DependenceHumansImage Processing, Computer-AssistedMaleMonoamine OxidaseCatecholaminesDopamine AgonistsKB220ZMonoamine OxidaseNeprilysinAbstinent heroin addictsbrain reward circuitrydopaminefMRIKB220Z

Identifiers

PMID25526228
PMCPMC4979602
OpenAlexW2136246479

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.